ClinicalTrials.gg
RecruitingNCT07384052INI-SCIUpdated Sep 15, 2026

Safety and Feasibility of Intranasal Insulin in Patients With Spinal Cord Injury

A Phase 1 interventional study of Regular Insulin and 0.9 % Normal Saline in Spinal Cord Injury, sponsored by HealthPartners Institute. Recruiting at 1 site in United States. Open to participants aged 18 Years to 84 Years. Per ClinicalTrials.gov, last updated 2026-09-15.

Sponsored by HealthPartners Institute · Phase 1, Interventional, and Other

From the registry’s dates

  • Started Feb 2026; still recruiting 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
12
Allocation
Randomized
Ages
18 Years to 84 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 968 studies in Spinal Cord Injuries with a site in United States — 250 open to participants now, 308 under way, 7 of them phase 3. Spinal Cord Injuries · United States.

Planned enrollment
597th of 836
12 · median 24
Started
2026
with 69 others
Phase 1
63 of 968
19 open now
Primary completion
2026-12
later than 90 of 307 live
Registered
923rd of 968
by date

Among the 968 studies in Spinal Cord Injuries with a site in United States, this one is the 597th largest by planned enrollment of the 836 interventional ones that give a count, is one of 70 that started in 2026, is one of 63 in phase 1, reaches primary completion later than 90 of the 307 other live ones, and was the 923rd registered.

Spinal Cord Injuries

2,026 studies on the registry are indexed under Spinal Cord Injuries; 540 are open to participants now.

Browse Spinal Cord Injuries studies →

Open to participants now

250 of the 968 studies in Spinal Cord Injuries with a site in United States are open now. Recruiting first, the newest first:

245 more — sign in →

All 250 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 376 Spinal Cord Injuries studies recruiting now, 167 (44%) set no upper age limit and 158 (42%) stop at 75 or younger; 41 take children under 18; 52 take healthy volunteers.

This study: 18 Years to 84 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 968 studies in Spinal Cord Injuries with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to find out whether insulin, a drug approved by the FDA for the treatment of diabetes mellitus, is safe when administered as a nasal spray (intranasally) to people who have experienced a spinal cord injury. While insulin nasal spray has been shown to be safe in many patient populations, it has not yet been studied in people with spinal cord injury. This study would be the first step to developing insulin nasal spray as a treatment for spinal cord injury in the future.

This study is recruiting up to 12 individuals who have experienced a spinal cord injury at least 4 months ago to administer either 76 IU insulin nasal spray or a placebo (inactive nasal spray) at home every day for up to 24 days. Participants will be asked questions about their health and symptoms related their spinal cord injury, and will have their blood collected throughout the study. Participants who are unable to administer the medication independently must have a study partner in order to participate.

03

Conditions studied

  • Spinal Cord Injury

Keywords

  • Insulin
  • Intranasal
  • Safety
  • Feasibility
  • Spinal Cord Injury
  • SCI
  • INI
04

Who can participate

Ages eligible
18 Years to 84 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Subject is ≥18 and \<85 years of age
  2. Subject has sustained a traumatic or non-traumatic spinal cord injury with American Spinal Injury Association (ASIA) rating A, B, C or D, complete or incomplete
  3. Subject sustained spinal cord injury at least 4 months before baseline visit
  4. Female subjects must have either: (1) a negative pregnancy test at the screening and treatment visits OR (2) be at least 2 years / surgically sterile
  5. The subject must be proficient in English in order to comply with instructions and measures for the study
  6. Subject is able to prepare and administer the study drug as outlined in the protocol or has a carer who is available to do so for the duration of the study
  7. Subject can provide written
  8. Subject has been on a stable regimen of medications for at least 30 days from baseline visit

Exclusion criteria

Exclusion Criteria:

  1. Subject is dependent on a ventilator or has a patent tracheostomy site
  2. Subject has recent history (within past 6 months) of recurrent autonomic dysreflexia, defined as a sudden rise in systolic BP greater than 20 mmHg or diastolic BP greater than 10 mmHg without rise in heart rate and accompanied by symptoms such as headache, facial flushing, sweating, nasal congestion, or blurry vision
  3. Subject has medical history and/or clinically determined disorders: chronic sinusitis, previous nasal and/or oto-pharyngeal surgery and severe deviated septum and/or other anomalies
  4. Subject has history of any of the following: active and significant central nervous system, psychiatric illness, pulmonary, or cardiovascular disorders or any other abnormality that inclusion would pose a safety risk to the subject as determined by investigator
  5. Subject has participated in a clinical trial investigation within 3 months of this study
  6. Subject has a history of allergy, , or other significant adverse reaction to insulin
  7. Subject is taking insulin for Type I or Type II diabetes
  8. Subject is pregnant or breast feeding
  9. Any other clinically relevant finding that would pose a safety risk to the subject as determined by the investigator
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
12 participants (estimated)

Study arms

  • Experimental
    Intranasal Insulin

    Regular Insulin (Novolin-R) 76 international units per day administered as 38 IU in one nostril twice daily (alternating nostrils) for 21+/-3 days

    Drug: Regular Insulin

  • Placebo comparator
    Placebo

    0.9% sodium chloride in one nostril twice daily (alternating nostrils) for 21+/- days

    Other: 0.9 % Normal Saline

Interventions

  • Administered Intranasally at 76 IU

    Also known as: Novolin-R

  • Other0.9 % Normal Saline

    Placebo Control

06

What researchers measure

Primary outcomes

  1. Safety measured by number of serious adverse events (SAE) and adverse events (AE)

    Total number of AEs/SAEs during the course of treatment. More AEs/SAEs indicates a less safe treatment. AEs counts will include total count and will be stratified by severity.

    Time frame: 3 weeks

Secondary outcomes

  1. Treatment adherence as assessed by participant Daily Drug Diaries

    Number of doses successfully administered as reported by participants in their daily drug diaries

    Time frame: 3 weeks

  2. Feasibility of virtual training as assessed by the Virtual Training Compliance Checklist

    Average score on virtual training compliance checklist, both arms combined

    Time frame: Baseline Visit

  3. Acceptability of virtual training as assessed by the Virtual Training and Feasibility and Acceptability Survey

    Total score on the Virtual Training Feasibility and Acceptability Survey, both arms combined

    Time frame: Baseline

  4. Feasibility of blood spot collection procedure as measured by a Blood Spot Procedure Compliance Checklist

    Participants will be trained to perform a blood spot collection procedure independently. Feasibility will be measured by the average score on blood spot procedure compliance checklist, both arms combined

    Time frame: Screening Visit

  5. Acceptability of Blood Spot Procedure, as measured by a Blood Spot Procedure Post-Training Acceptability Survey

    Acceptability of performing blood spot procedure independently will be measured by the average score on a blood spot procedure post-training acceptability survey, both arms combined

    Time frame: Screening Visit

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2026 (actual). Primary completion is estimated for Dec 2026, 10 months after the start.

Of 40 non-industry phase 1 interventional studies under Spinal Cord Injuries, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 55. This study's planned 10 months is below that.

Counting every sponsor, half of 51 studies reached it within 36 months; a quarter within 24 and three quarters within 55.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 26, 2026
First posted
Feb 3, 2026
StartActual
Feb 20, 2026
Primary completionEst.
Dec 2026
CompletionEst.
Jan 2027
Last update
Sep 15, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 15, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07384052
Collaborators
Uniformed Services University of the Health Sciences, Congressionally Directed Medical Research Programs
Responsible party
Sponsor
First posted
Feb 3, 2026
Start date
Feb 20, 2026
Primary completion
Dec 2026 (estimated)
Completion
Jan 2027 (estimated)
Last update
Sep 15, 2026

Study contacts

Meghan E O'Brien, MPH
Contact
Meghan.E.Obrien@HealthPartners.com
651-495-6363
Bethany K Crouse, PhD
Contact
Bethany.K.Crouse@HealthPartners.com
Leah R Hanson, PhD
principal investigator · HealthPartners Institute
Kimberly Byrnes, PhD
principal investigator · Uniformed Services University of the Health Sciences

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Insulin

Start the discussion